FDA will review Eisai and Biogen’s Alzheimer’s treatment Leqembi with decision on full approval expected in early July

By CNBC
| March 07, 2023

The Food and Drug Administration will make a decision on whether to fully approve Eisai and Biogen’s Alzheimer’s treatment Leqembi by July 6, the companies announced Monday.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...